Why the study?
Selecting an optimal DAPT regimen after PCI remains an evolving challenge, prompting interest in individualized strategies to balance efficacy and safety.
How can the duration of dual antiplatelet therapy be individualized after coronary stenting to optimize efficacy and safety?
How can the duration of dual antiplatelet therapy be individualized after coronary stenting to optimize efficacy and safety?
Individualizing DAPT duration after coronary stenting, rather than applying a standard 12-month regimen, is increasingly supported by evidence to balance ischemic and bleeding risks.
Answers are grounded in this paper and cite their sources.
May support tailoring DAPT duration post-stenting to balance risks; leaves open prospective trials before practice change.
Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor, is the cornerstone of post-percutaneous coronary intervention treatment to prevent stent thrombosis and reduce the risk of adverse cardiovascular events. The selection of an optimal DAPT regimen, considering the interplay of various antiplatelet agents, patient profiles, and procedural characteristics, remains an evolving challenge. Traditionally, a standard duration of 12 months has been recommended for DAPT in most patients. While contemporary guidelines provide general frameworks, DAPT modulation with longer or shorter treatment courses followed by aspirin or P2Y12 inhibitor monotherapy are evolving towards an individualized strategy to optimize the balance between efficacy and safety. This review comprehensively examines the current landscape of DAPT strategies after coronary stenting, with a focus on emerging evidence for treatment individualization.
No takes yet. Share an insight, caveat, or question.
Carciotto et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: